Jasper Therapeutics rises on prelim early-stage data for skin disease drug

Jasper Therapeutics

14/10/2024 13:42

** Shares of drug developer Jasper therapeutics  JSPR.O  up
1.4% at $15.24 in premarket trading
        ** JSPR says prelim data shows its experimental skin
disorder drug was well-tolerated in an early- to mid-stage study
    ** Co is testing the safety and tolerability of its drug,
briquilimab, in adult patients with cold urticaria, which causes
hives and itches after the skin is exposed to something cold 
    ** Fourteen of 15 patients enrolled so far across two dose
groups achieved clinical response, an indicator that shows
therapeutic effect of drug
    ** In the higher dose group, 10 of 12 patients experienced a
complete response and 1 showed partial response
    ** Co plans to enroll 27 patients across three dose groups
and expects to present full data from the study in H1 2025
    ** Stock almost doubled YTD, as of last close

    
  

 (Reporting by Sruthi Narasimha Chari in Bengaluru)
 ((Sruthinarasimha.chari@thomsonreuters.com))